Key result
Elevated biomarkers were evaluated for their prognostic implication on six-month mortality in 1,951 patients with acute coronary syndromes, but results were not reported in the truncated abstract.
Why the study?
Do elevated cardiac biomarkers predict six-month mortality differently in diabetic versus non-diabetic patients admitted for acute coronary syndromes?
Cohort (n=1,951)
No
Do elevated cardiac biomarkers predict six-month mortality differently in diabetic versus non-diabetic patients admitted for acute coronary syndromes?
No takes yet. Share an insight, caveat, or question.
Biomarker prognostic value for six-month ACS mortality by diabetes status remains unclear; leaves open differential prediction in diabetics versus non-diabetics.
Reza Fazel (2005) conducted a cohort in Acute coronary syndromes (n=1,951). Elevated biomarkers (CK-MB and troponin) vs. Normal biomarkers was evaluated on Six month mortality. Elevated biomarkers were evaluated for their prognostic implication on six-month mortality in 1,951 patients with acute coronary syndromes, but results were not reported in the truncated abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: